Introduction
============

Lung cancer is one of the most common malignant tumors in the world, and non-small cell lung cancer (NSCLC) accounts for more than 75% of all lung cancer cases[@B1], [@B2]. The identification of oncogenic mutations using variant sequencing techniques has been a routine clinical practice, which may guide selection of target agents and help to improve the clinical outcomes of lung cancer patients [@B3]-[@B7]. It is easy for cancer cells to develop resistance to targeting therapeutic drugs, which makes it hard to absolutely cure cancers [@B8], [@B9]. Intra-tumor genetic heterogeneity has been detected in previous studies using massively parallel sequencing analyses of multiple regions of primary lung cancer[@B10], [@B11], and this may be one of the main reasons for the resistance to targeted therapies. It is plausible that the metastatic process and the progression from primary to metastatic disease may result in genetic heterogeneity, along with molecular evolution [@B11].

The most common metastatic site of lung cancer is regional lymph nodes (LN). The spread of cancer cells from the primary tumor to regional lymph nodes is the main poor prognostic factor in NSCLC of stage I-III [@B12], [@B13]. The analysis of mutations of both the primary tumor and LN metastasis lesion is of great importance to understand the molecular evolutionary processes of lung cancer, and the process of lymphatic metastasis [@B14]. This would also help to develop a suitable therapeutic guide, and prolong the survival of patients with locally advanced NSCLC [@B15]. In the present study, genetic mutations in 1,408 key cancer genes were analyzed by hybridization capture-based massively parallel sequencing assay to define the extent of genetic heterogeneity between primary tumors and their respective LN metastasis and reflect the genetic evolutionary process of lymphatic metastasis in locally advanced NSCLC.

Materials and Methods
=====================

Patients and samples
--------------------

This study was approved by the Local Ethics Committee of Xiangya Hospital of Central South University. All patients provided a written informative consent. A total of 37 patients pathologically diagnosed and confirmed with NSCLC (including 14 lung squamous cell carcinoma (LUSC) and 23 lung adenocarcinoma (LUAD)) and a LN metastasis lesion, but without distant metastasis, were enrolled into the present study. Blood samples, primary tumor tissues and metastasis LN were collected from each patient. Frozen sections were made from the freshly frozen tumor tissues and metastasis LN. One slide of each tissue sample was lightly stained with hematoxylin and eosin (H&E) to re-examine the presence of cancer cells. The tumor cell content was calculated by an independent lung pathologist. The histopathologic assessment confirmed that all collected tumor tissue samples had ≥10% viable tumor cell content. The baseline characteristics of the included patients are presented in Table [1](#T1){ref-type="table"}.

Targeted sequencing
-------------------

Genomic DNA was extracted from two 4-μm fresh frozen tissue slices using a black PREP FFPE DNA Kit (Analytik Jena, GER). The DNA samples were quantified using a Qubit dsDNA HS Assay kit (Life Technologies, USA).

For sequencing, the genomic DNA was first sheared into 150-200 bp fragments using the Covaris M220 Focused-ultrasonicatorTM Instrument (Covaris, Massachusetts, USA). Next, the fragment DNA libraries were constructed using a KAPA HTP Library Preparation Kit (Illumina platforms) (KAPA Biosystems, Massachusetts, USA), according to manufacturer\'s instructions. Subsequently, the captured DNA fragments were sequenced using the Illumina Novaseq 6000 sequencing system, and the paired-end 150-bp was read using a custom capture panel (Genecast, Beijing, China). A total of 1,407 genes associated with cancer diagnosis and prognosis were identified. The raw sequencing data was de-multiplexed using the BCL2FASTQ software into individual paired-reads FASTQ files. The sequencing reads were eventually aligned against the hg19 reference genome using the BWA MEM software with default parameters sorted, and indexed with Samtools. The duplicated reads from tumor tissues and adjacent tissues were marked by the Picard MarkDuplicate tool, and were excluded from subsequent analyses. Further reads and mapping qualities were evaluated using FastQC and Samtools flagstat. The average unique sequence coverage was at least 900x for lymphocytes and 2400x for tumor tissue samples.

Single nucleotide variants (SNV) and Indel Calling
--------------------------------------------------

Paired sample variant calling on tumors were performed using matched adjacent tissues as the baseline reference. Varscan2 somatic calling was initially employed to detect somatic single nucleotide polymorphisms(SNPs) and Indels using loose parameters, while the calling results were subsequently filtered with custom and more stringent criteria. Especially in tumor tissue samples, merely bases with a depth of over 40x were considered. Both tumor somatic variants (SVs) were required to have at least one support read for each strand with a background *P*-value under 0.05. In addition, the minor allele frequency for the tumor was not less than 1%. Among the SVs, those with a *P*-value \<0.05, a deeper depth of 100x, and an allele frequency of over 5% were filtered and termed as SVs in the present study.

Furthermore, common variants and potential background noises introduced by the platform were also excluded, in order to ensure the reliability of the data. In particular, SVs with a population frequency of over 0.5%, according to the ExAC database or 1,000 Genomes database, were excluded. In addition to these two databases, a sample pool based on 30 healthy Chinese donors was also used as a standard normal database to identify either prevalent germline mutations in the Chinese population or technical artifacts prevailing in the sequencing platform. Variants with prevalence of no less than 20% in the standard normal database were blacklisted in the present study, and excluded from the downstream analysis. In addition, variants with no less than 20% prevalence among a larger real-life patient sample population, which contains more than 5,000 samples in different cancer types, as tested by Genecast, Beijing, China on a Novaseq 6000 sequencer, were considered as sequencing-specific errors, and were also excluded from further analysis.

Copy number variation (CNV) calling
-----------------------------------

A negative control copy number baseline was constructed using all blood cell samples obtained from patients, and the CNV from FFPE samples was called for each patient using a CNV kit. A software package CNV kit that applies both sequencing target region reads and nonspecifically captured off-target reads was used to reduce the bias introduced by target region sequencing, and improve the somatic CNV detection resolution. During the software working procedure, three main sources of bias induced the extraneous variability of the sequencing read depth, which include GC content, target footprint size and spacing, and repetitive sequences, and these were evaluated and corrected. The thresholds of copy number ≥3 and ≤1.2 were used to categorize altered regions as CNV gains (amplification) and copy number losses (deletions).

Mutational signature analysis
-----------------------------

6 categories of base substitutions exist, namely, C \> T, C \> A, C \> G, T \> C, T \> G, and T \> A. There will be a total of 96 substitution types, when the 5′ and 3′ flanking nucleotides of a specific mutated base are taken into consideration. The proportion of specific trinucleotide mutational signature in primary lesion and LN metastasis lesion was first compared in both LUAD and LUSC. Then, R package deconstructSigs [@B16] was used to extract the underlying specific trinucleotide mutational signature in every each sample, by using the 30 signatures documented by the COSMIC as reference, which can be obtained from COSMIC (<https://cancer.sanger.ac.uk/cosmic/signatures>). After that, the mean weights of different signatures in LN metastasis and primary tumor were calculated in both LUAD and LUSC.

Enrichment analysis of LN metastasis exclusive somatic mutations (LME-SMs)
--------------------------------------------------------------------------

Somatic variants that can be detected in the LN metastasis, but not in the primary tumor, were termed as LME-SMs. To study the functions of LME-SMs, Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway enrichment analysis was performed using R package clusterProfiler v3.6.0[@B17]. The GO functional analysis consisted of three categories: biological process (BP), cellular component (CC) and molecular function (MF). In the present study, an adjusted P value ≤0.1 was set as the cut-off criterion for the enrichment analysis.

Results
=======

Mutational landscape of primary lung cancer and its synchronous lymphatic metastasis
------------------------------------------------------------------------------------

In 23 patients with LUAD, a total of 116 and 84 mutations were discovered in the primary lesion and LN metastasis lesion, respectively. Among these, a total of 45 mutations were concordant, which could be both detected in the primary and metastasis lesions (Fig. [1](#F1){ref-type="fig"}A), leading to a concordance rate of 29.0% at the mutation site (45/155). TP53 and EGFR were the two most frequently mutated genes in both primary lesion (14/23 \[61%) and 8/23 \[35%\], respectively) and LN metastases lesion (9/23 \[39%\] and 6/22 \[26%\], respectively) (Fig. [2](#F2){ref-type="fig"}A). In 14 patients with LUSC, a total of 74 and 37 mutations were discovered in the primary lesion and LN metastasis lesion respectively. Among these, a total of 17 mutations were concordant, which could be both detected in the primary and metastasis lesions (Fig. [1](#F1){ref-type="fig"}B), leading to a concordance rate of 18.1% (17/94). In LUSC, TP53 was the most frequently mutated gene in both primary lesion (11/22 \[50%\]) and LN metastases lesion (9/22 \[41%\]) (Fig. [2](#F2){ref-type="fig"}B). In conclusion, LUAD (29.0%) showed higher concordance rate in mutations between the primary and metastasis lesions than LUSC (18.1%). Besides, more mutations were discovered in the primary lesion than LN metastasis lesion in both LUAD and LUSC, indicating that tumor mutation burden is higher in the primary lesion than that in LN metastasis lesion.

CNVs of primary lung cancer and its synchronous lymphatic metastasis
--------------------------------------------------------------------

In 23 patients with LUAD, 245 and 143 CNVs were found in the primary lesions and LN metastasis lesions, respectively. Among these, a total of 19.4% (63/325) CNVs were concordant between primary tumors and their matched metastases (Fig. [1](#F1){ref-type="fig"}C). In addition, it was found that 44.1% of CNVs (63/143) detected in LN lesions were mainly preserved from the primary lesions. In 14 patients with LUSC, 149 and 81 CNVs were found in these primary lesions and LN metastasis lesions, respectively. Among these, a total of 15.0% (30/230) CNVs were concordant between primary tumors and their matched metastases (Fig. [1](#F1){ref-type="fig"}D). In addition, it was also found that 37% of CNVs (30/81) detected in LN lesions were mainly preserved from their primary lesions. Furthermore, the copy number profiles in each patient demonstrated that the copy number variants were quite similar between the primary tumor and its respective metastasis in both LUAD (Fig. [3](#F3){ref-type="fig"}A) and LUSC (Fig. [3](#F3){ref-type="fig"}B), suggesting that the copy number profiles were largely preserved through the progression of the lymphatic metastasis.

Mutation signature in primary lung cancers and LN metastases
------------------------------------------------------------

Regarding the mutational context, a strong enrichment of C \> T transitions was observed in the primary tumor and LN metastasis in bolt LUAD and LUSC, especially at the CpG dinucleotides, which is denoted as signature 1 documented in the COSMIC Mutational Signature Framework (Fig. [4](#F4){ref-type="fig"}A and [4](#F4){ref-type="fig"}B). The signature 1 is more dominant in LN metastasis than primary tumor, suggesting that the spontaneous deamination of cytosine contributes to the accumulation of mutations during tumor development and migration in both LUAD and LUSC(Fig. [4](#F4){ref-type="fig"}C and [4](#F4){ref-type="fig"}D) [@B18].

Functions of LME-SMs
--------------------

LME-SM genes enriched in BP terms were mainly associated with peptidyl-tyrosine phosphorylation, and peptidyl-tyrosine modification in both LUAD and LUSC (Fig. [5](#F5){ref-type="fig"}A). LME-SM genes enriched in MF terms were mainly associated with protein tyrosine kinase activity, transmembrane receptor protein kinase activity, and transmembrane receptor protein kinase activity in both LUAD and LUSC (Fig. [5](#F5){ref-type="fig"}C). LME-SM genes enriched in CC terms were mainly associated with focal adhesion, cell-substrate adherent junction, cell-substrate adherent junction in LUSC. But no enrichment in CC terms was available in LUAD (Fig. [5](#F5){ref-type="fig"}B). Furthermore, the KEGG pathway enrichment analysis demonstrated that the LME-SM genes were mainly enriched in the PI3K-Akt signaling pathway, the MAPK signaling pathway, and the Ras signaling pathway in both LUAD and LUSC (Fig. [5](#F5){ref-type="fig"}D).

Discussion
==========

To our knowledge, the current study represents the largest set of matched primary lung tumors and metastases so far to explore the genetic heterogeneity in the process of tumor migration and reflect the genetic evolutionary process of lymphatic metastasis in locally advanced NSCLC using large scale of key cancer genes. The results confirm that genomic heterogeneity exists between primary lesion and LN metastasis lesion, and may be the reason for the observed heterogeneous responses to therapy, and the eventual development of resistance to target agents in cancers. Mutations in genes related to cell migration and metastasis may explain the process of progression in NSCLC.

Regarding the mutational context, our results showed that the signature 1 documented in the COSMIC Mutational Signature Framework was both enriched in primary lesion and LN metastasis lesion in both LUAD and LUSC. But it was more prominent in LN metastasis lesion. The study by Chen *et al.* [@B19] showed that signature 1 was also strongly enriched in both 45 pairs of esophageal squamous cell carcinoma specimens and the matched dysplasia specimens. All these results suggest that the spontaneous deamination of cytosine may contribute to the accumulation of mutations during tumorigenesis and metastasis. But the mechanisms underlying the generation of mutation signature 1 remain unclear.

In the present cohort, TP53, EGFR, PIK3CA, BRAF, which have been known as cancer driver genes, were the most frequently mutated genes in primary tumors and LN metastases. EGFR mutation, as a targetable mutation, is of great significance in clinical practice in LUAD. Among the 23 LUAD patients enrolled in the present study, seven patients had EGFR targetable hotspot mutations (including L858R, 19del, and T790M) in the tumor sample, while six patients had EGFR mutations in LN samples. The discordance rate in mutations between tumor and LN samples was 13.0% (3/23). For patient P7870, a sensitive EGFR mutation L858R was detected in the metastasis LN tissue, but not in the primary tumor, which implies that mutational profiling in metastatic samples would be of more value. For patient P5082 and P5249, EGFR T790M mutations and EGFR 21del were only detected in primary tumors, respectively. These results were consistent with the observations reported by Park *et al.* \[20\]and Wang *et al.[@B21]*, in which a considerable discrepancy(11.9% and 14.5%, respectively) in EGFR mutations generates between primary tumors and metastatic LN, suggesting that genetic heterogeneity originates at the molecular level during the process of metastasis. Furthermore, a considerable proportion of mutations were found to be different between primary tumors and metastatic lesions, which is in agreement with the observation reported by Um *et al.*, in which a considerable proportion of NSCLCs exhibited unique mutations in metastatic LN, supporting that clonal evolution occurs at the molecular level during the process of metastasis[@B22]. Since considerable tumor heterogeneity exists at the molecular level during the process of metastasis, multiple biopsies and sequencing strategies for different tumor regions are required.

It is noteworthy that more mutations were found in the primary tumor in both LUAD and LUSC, when compared to the paired LN metastasis, indicating that tumor mutation burden is higher in primary lesion than that in LN metastasis lesion. This was also observed by Kim *et al.[@B23]*, in which there was a higher chance of non-synonymous mutation in primary tumors than in metastatic LNs. The mechanisms underlying the decrease in mutations in metastatic lesions remain unclear.

In the present study, the copy number profiles in the primary tumor and its respective metastasis lesion were quite similar in both LUAD and LUSC. This was consistent with the observation reported by Schrijver *et al.[@B24]*, in which the copy number profiles were largely preserved through the progression of the metastasis in breast cancer. These results suggest that the copy number alteration, as a punctuated burst of evolution, is more likely to be preserved from its primary lesion.

It has been known that the PI3K-Akt, MAPK and Ras signaling pathways regulate cell proliferation, differentiation and migration, and are closely associated with carcinogenesis and disease progression [@B25], [@B26]. In our study, the KEGG pathway enrichment analysis demonstrated that LME-SM genes were enriched in the PI3K-Akt, MAPK and Ras signaling pathways in both LUAD and LUSC. These results imply that LN metastasis may be associated with the PI3K-Akt, MAPK and Ras signaling pathway in NSCLC. LUSCs are characterized histopathologically by the presence of intercellular bridges and high levels of proteins relevant to intercellular junctions, which distinguished from LUAD [@B27]. Previous studies indicated that altered genes that code for proteins involved in the formation of intercellular adhesion and cell-substrate adhesion were closely related to tumor migration and metastasis of LUSC [@B27], [@B28]. Our GO cellular component enrichment analysis revealed that the LME-SM genes were mainly associated with cell focal adhesion, cell-substrate adherent junction, cell-substrate adherent junction in LUSC but not LUAD, indicating that the malfunction of intercellular adhesion, cell-substrate adhesion and junction presented exclusively in LUSC but not LUAD.

The present study was limited by the relatively small sample size and limited capacity of targeted massively parallel sequencing, which may not uncover all the mutations involved in the progression, from primary lung cancer to metastatic disease. Whole exome sequencing and multi-region sampling of primary tumor and metastasis tumor tissues are required for the comprehensive understanding of the landscape of genetic alterations, and for guiding targeted therapy in locally advanced lung cancer.

In conclusion, there were differences in the repertoire of somatic mutations and CNVs, which even affected driver and potentially targetable genes in NSCLC. The genetic heterogeneity in cancer lesions from the same origin reminds people to develop multi-functional drugs to target metastatic lesions with different genetic profiles.
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###### 

Baseline characteristics of the patients

  Characteristic        Number (%)
  --------------------- ------------
  **Age (year)**        
  ≥60                   21(56.8%)
  \<60                  16(43.2%)
  **Gender**            
  Male                  25(67.6%)
  Female                12(32.4%)
  **Smoking history**   
  Smoking               24(64.9%)
  Nonsmoking            13(35.1%)
  **Histology**         
  LUAD                  23(62.2%)
  Squamous              14(37.8%)
  **Stage**             
  IIb                   11(29.7%)
  IIIa                  21(56.8%)
  IIIb                  5(13.5%)
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